BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17143323)

  • 1. RNAi: a novel strategy for the treatment of prion diseases.
    Kong Q
    J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
    Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
    J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of cell lines to prion toxicity aided by phospho-ERK expression.
    Uppington KM; Brown DR
    J Neurochem; 2008 May; 105(3):842-52. PubMed ID: 18088369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific inhibition of pathological prion protein accumulation by small interfering RNAs.
    Daude N; Marella M; Chabry J
    J Cell Sci; 2003 Jul; 116(Pt 13):2775-9. PubMed ID: 12759373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
    White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion encephalopathies of animals and humans.
    Prusiner SB
    Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA molecules stimulate prion protein conversion.
    Deleault NR; Lucassen RW; Supattapone S
    Nature; 2003 Oct; 425(6959):717-20. PubMed ID: 14562104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of antibody fragments for immunotherapy of prion diseases.
    Campana V; Zentilin L; Mirabile I; Kranjc A; Casanova P; Giacca M; Prusiner SB; Legname G; Zurzolo C
    Biochem J; 2009 Mar; 418(3):507-15. PubMed ID: 19000036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prions and their biology].
    Gasset M; Westaway D
    Rev Neurol; 2000 Jul 16-31; 31(2):129-32. PubMed ID: 10951668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring.
    Chesebro B; Race B; Meade-White K; Lacasse R; Race R; Klingeborn M; Striebel J; Dorward D; McGovern G; Jeffrey M
    PLoS Pathog; 2010 Mar; 6(3):e1000800. PubMed ID: 20221436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropathological phenotype in transgenic mice expressing different prion protein constructs.
    DeArmond SJ; Yang SL; Cayetano-Canlas J; Groth D; Prusiner SB
    Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):415-23. PubMed ID: 7913760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient in vitro amplification of a mouse-adapted scrapie prion protein.
    Murayama Y; Yoshioka M; Yokoyama T; Iwamaru Y; Imamura M; Masujin K; Yoshiba S; Mohri S
    Neurosci Lett; 2007 Feb; 413(3):270-3. PubMed ID: 17174030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenetic investigations of prion diseases of humans and animals.
    Prusiner SB
    Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):239-54. PubMed ID: 8097053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of misfolding: prion disease behavioral and physiological impairments recover following postnatal neuronal deletion of the PrP gene.
    Federoff HJ; Mhyre TR
    Neuron; 2007 Feb; 53(3):315-7. PubMed ID: 17270727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental influence of the cellular prion protein on the gene expression profile in mouse hippocampus.
    Benvegnù S; Roncaglia P; Agostini F; Casalone C; Corona C; Gustincich S; Legname G
    Physiol Genomics; 2011 Jun; 43(12):711-25. PubMed ID: 21406608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of prion diseases and prion diversity in mice.
    Carlson GA; DeArmond SJ; Torchia M; Westaway D; Prusiner SB
    Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):363-9. PubMed ID: 7913753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).
    Gong HS; Guo Y; Tian C; Xie WL; Shi Q; Zhang J; Xu Y; Wang SB; Zhang BY; Chen C; Liu Y; Dong XP
    Int J Mol Med; 2012 Sep; 30(3):569-78. PubMed ID: 22692785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.